Keyword: Nexium

In its latest asset selloff, AZ hived off rights to asthma med Alvesco and rhinitis drugs Omnaris and Zetonna to Covis Pharma for $350 million.

In its latest asset sale, AstraZeneca sold certain rights to Vimovo and Nexium to Grünenthal for more than $800 million.

What's notable about the 10 best-selling drugs over the past 25 years? Here's a hint: Today's king is passing, and the next has a long life ahead.

Repeated drug price hikes have caught plenty of criticism lately, but the attention isn't dissuading everyone.

A decade in biopharma has a way of featuring megablockbuster patent losses—and we mean mega, with a total $915B in lifetime sales.

Say what you want about AstraZeneca’s castoff strategy, but it helped drive another earnings beat for the lacking-in-sales drugmaker to kick off the year.

Facing the prospect of lower U.S. revenue next year, AstraZeneca has put 700 more stateside jobs on the chopping block.

The purple pill has a new ad agency home. Pfizer moved its OTC heartburn drug Nexium from ad agency Leo Burnett to Grey after a review.

In 2013, it looked as if AstraZeneca and Ranbaxy could face billions in damages in a lawsuit alleging they struck an illegal deal to block a Nexium generic. Now, that cloud has lifted.